CD8A and neoplasm: As expected, intravenous administration of CBD-CCL4 can remarkably enhance the recruitment of CD103+ DCs and CD8+ T cells, exhibiting significant anti-tumor effects in multiple tumor models in combination with ICB immunotherapy [26].